Pro Medicus, Ltd. · ASX:PME
Pro Medicus — Shareholder Meeting (November 2011)
32 slides from Pro Medicus's shareholder meeting presentation, Nov 18, 2011
Slide 1: Annual General Meeting November 2011
For personal use only Annual General Meeting November 2011
Slide 2: Chairman's Address
Chairman’s Address AGM 2011 For personal use only • Overview • Non Executive Directors • Mel Ward Scholarship • CEO/Management Team
Slide 3: CEO Address
For personal use only Annual General Meeting CEO Address
Slide 4: Year in Review
Year in Review For personal use only • One of the most difficult years in company’s history. • Revenue and Profit negatively impacted. • Number of one-off, legacy factors. • Currency – large negative impact. • Delay in release of RIS new technology platform.
Slide 5: Year in Review
Year in Review For personal use only • FY2011 to be turning point in cycle • Continued our investment in R&D • Company remains debt free • Cash reserves of $3.26M (as of 30/6/11)
Slide 6: Milestones – New Technology Platform Coral
Milestones – New Technology Platform “Coral” For personal use only • New technology platform “Coral” now in pre release • Speed of product development has increased • Technology is leading edge • Feedback from customers – extremely positive • Multi lingual support • One product - suitable for all ma
Slide 7: Coral – everything is new!
“Coral” – everything is new ! For personal use only
Slide 8: Milestones - Visage
Milestones - Visage For personal use only • Visage 7.0 - leading thin client technology • Well positioned in growing 3D PACS market. • Highly modular solution: – PACS – Universal viewer – Referrer distribution – Teleradiology/Remote reading. • Addresses ~ 85% of market:
Slide 9: Milestones - Visage
Milestones - Visage For personal use only • Significant ongoing Product development • Improved robustness and scalability • Visage Referrer Access Gateway • Visage “Ease” - iPad and iPhone
Slide 10: Milestones – Visage EASE Mobile
Milestones – Visage “EASE” Mobile For personal use only • Solid year of Product development • Improved robustness and scalability • Referrer Access Gateway • Visage “Ease” - iPad and iPhone Visage EASE – 1Phone/iPad App
Slide 11: North America
North America For personal use only • Worlds biggest market. • Visage brand has presence. • Technology leader in thin client 3D PACS. • A large number of opportunities. • Market fragmented and will consolidate.
Slide 12: US – Management Changes
US – Management Changes For personal use only • Brad Levin – General Manger & Global Head of Marketing • Joined August 2011 • Industry veteran with excellent track record. • Already having positive impact • Will lead team at RSNA conference
Slide 13: US – Management Changes
US – Management Changes For personal use only • Bobby Roe – Director of Solutions Architecture and Customer Experience • Joined October 2011 • Wealth of industry experience. • To spearhead technical and customer focused activities.
Slide 14: North America – Gaining Momentum
North America – Gaining Momentum For personal use only • CDI – Referrer Distribution. • CIRA - Universal Viewer. • Imaging Endpoints - Thin client 3D. • Rays - Teleradiology.
Slide 15: North America – RSNA 2011
North America – RSNA 2011 For personal use only • Worlds biggest market. • Visae brand has presence. • Technology leader in thin client 3D PACS. • Starting to make in roads.
Slide 16: Australian – Management Changes
Australian – Management Changes For personal use only • Danny Tauber – General Manger Australia • Previously Chief Operations Manager • Has been with the company over 17 years. • Positive impact on customer services • Supervising team for Coral roll out in Australia
Slide 17: Europe
Europe For personal use only • Key growth market. • Increased emphasis on direct sales channels • Growing client base Germany, UK and Belgium • Opportunities in 2013 NHS PACS refresh. • Keen interest in other European countries.
Slide 18: European – Management – Malte Westerhoff
European – Management – Malte Westerhoff For personal use only • Co Founder and co-developer of Visage platform • Leads team of 41 people • Building direct sales capability • Forming platform for future European growth
Slide 19: European – Management – Detlev Stalling
European – Management – Detlev Stalling For personal use only • Co Founder and co-developer of Visage platform • Head of R&D • Heads strong development team • Responsible for both Visage and Amira R&D
Slide 20: European Opportunities
European Opportunities For personal use only • Eurozone - financial uncertainty • May affect health spend in short term • Purchasing decisions likely to take longer • Need to form partnerships to address NHS market • Opportunities for Visage PACS and “Coral”
Slide 21: Pro Medicus – e-health
Pro Medicus – e-health For personal use only 20 • Revenue ~ $1.9M per annum. • Scalable and transaction based. • Currently only in Australia – potential European and US opportunities.
Slide 22: Pro Medicus – Amira
Pro Medicus – Amira For personal use only 21 • 3D Toolkit for Life Sciences • Sold through Web Store • Sales still growing strongly - 15% plus pa • Increases awareness of Visage brand
Slide 23: Visage – OEM Business
Visage – OEM Business For personal use only 22 • Still important in terms of European revenue • Key contracts performing well • Sales in Europe and US
Slide 24: Visage – OEM Business
Visage – OEM Business For personal use only 23 • Solid contributor to European revenue • Key contracts performing well • OEM business to continue in Europe and US
Slide 25: Mel Ward Scholarship
For personal use only Mel Ward Scholarship
Slide 26: Thank you to our Directors and staff
For personal use only Thank you to our Directors and staff for all of the efforts throughout the year
Slide 27: Annual General Meeting November 2011
For personal use only Annual General Meeting November 2011
Slide 28: Resolution of Shareholders – Remuneration Report
RESOLUTION OF SHAREHOLDERS For personal use only • Resolution 2 – To adopt the Remuneration Report (non binding) FOR OPEN AGAINST 61,090,797 97,237 19,599,361 75.62% 0.12% 24.26%
Slide 29: Resolution 3A – Elect Director Roderick Lyle
RESOLUTION OF SHAREHOLDERS For personal use only • Resolution 3A – To elect as a Director Roderick Lyle FOR OPEN AGAINST 80,763,259 337,084 155,637 99.39% 0.41% 0.19%
Slide 30: Resolution 3B – Elect Director Peter Kempen
RESOLUTION OF SHAREHOLDERS For personal use only • Resolution 3B – To elect as a Director Mr Peter Kempen FOR OPEN AGAINST 80,708,094 330,884 25,102 99.28% 0.41% 0.32%
Slide 31: Resolution – Incentive Options to Roderick Lyle
RESOLUTION OF SHAREHOLDERS For personal use only • Resolution 4 – Approval of incentive options to Mr Roderick Lyle FOR OPEN AGAINST 60,814,864 271,054 19,976,201 75.02% 0.33% 24.64%
Slide 32: Resolution – Long Term Incentive Plan
RESOLUTION OF SHAREHOLDERS For personal use only • Resolution 5 – Approval of Long Term Incentive Plan FOR OPEN AGAINST 61,041,090 277,254 19,734,525 75.31% 0.34% 24.35%